Tamtam Try Tamtam free
10x Genomics logo

10x Genomics account plan

Cell analysis tools

At a glance

10x Genomics sells single cell and spatial biology instruments, consumables and software; FY2025 revenue was $642.8 million.

10x Genomics is a life sciences tools company based in Pleasanton, California. It sells instruments, consumables and bundled software for single cell (Chromium) and spatial (Visium, Xenium, and since 2026 Atera) biology to academic, government, biopharma and biotech researchers in over 50 countries. FY2025 revenue was $642.8 million (+5%), net loss narrowed to $43.5 million, and the company had 1,178 employees at December 31, 2025. About 44% of revenue came from outside North America; it reports a single operating segment.

Business units

Strategic priorities

Ramping the Atera spatial platform
Atera shipped from late September 2026; the company now expects about 50 instruments shipped by year-end, up from about 40, and sees about 50 a quarter as the right rate going into 2027. Production, installation and training are the constraint, not demand.
Growing biopharma demand
Nearly all of the world's top 20 biopharma companies have bought Atera systems or services through Catalyst Research Services, which had more than 100 customers book projects in 5 months. Flex Apex is scaling rapidly in biopharma.
AI and software
Management calls AI a structural tailwind as large data-generation efforts aim to train models. The Sentira cloud analysis platform uses NVIDIA computing for spatial data and Anthropic's Claude for agentic single cell analysis.
Entering clinical markets
Collaborations with Fred Hutch, Cleveland Clinic and Lausanne University Hospital in oncology, and an internal CLIA lab targeted for launch next year; today products are research use only.
Cost discipline
A 2025 reduction in force cost about $10.6 million; R&D fell 10% and SG&A 8% in FY2025, and operating expenses excluding settlement gains are expected to modestly decrease in 2026.

Latest results

In Q3 2026 (quarter ended September 30, 2026), revenue was $150.7 million, up 1% from $149.0 million. Consumables grew 5% to $134.3 million, with Spatial consumables up 16%, while instruments fell 43% to $6.9 million as customers held back Xenium and Visium purchases ahead of Atera. Gross margin rose to 75% from 67%, operating loss narrowed to $16.1 million and net loss was $19.4 million; cash and marketable securities were $575.7 million. FY2026 revenue guidance was raised to $625 million to $635 million, 4% to 6% growth excluding settlement revenue, with Q4 gross margin expected in the low to mid-60s.

Investments and deals

Scale Biosciences acquisition
Acquired in August 2025 for $9.2 million cash and $13.5 million in shares upfront, with a Q1 2026 milestone paid ($10.0 million cash and $8.7 million in shares) and up to $30.0 million contingent consideration; it adds QuantumScale kits.
Proteintech Genomics acquisition
Bought on June 8, 2026 for $6.1 million in cash, with a 10-year supply agreement valued at $12.4 million, to add high-plex proteomics to Atera and Chromium.
Capital expenditure
Capex planned at $10 million to $15 million over the next 12 months, per the Q3 2026 10-Q.
Patent enforcement
10x sued Illumina in October 2025 over spatial and single cell products, with trials scheduled for January 2028 and April 2028; Scale Bio won a jury verdict against Parse in August 2026.

Challenges and risks

Academic funding pressure
A substantial share of revenue depends on U.S. academic and NIH funding; the CEO describes the academic environment as one where the dollars are still not flowing out.
Atera transition risk
Customers delayed Xenium and Visium purchases ahead of Atera; early units may show reliability issues, inventory could become excess, and 2027 margins are expected to be lower in an instrument-heavy year.
Price declines
Average selling prices are expected to decline as lower-priced products such as Flex Apex grow, which puts pressure on top line revenue.
Trade and supply chain
Exposure to U.S. tariffs and China trade tensions (China was about ten percent of 2025 revenue), single-source suppliers, and memory component prices that increased substantially during 2026.

What leadership says

“demand is not the bottleneck. We have lots and lots of orders”

Serge Saxonov, Co-Founder and Chief Executive Officer · Q3 2026 earnings call, November 2026

“Atera is the future”

Serge Saxonov, Co-Founder and Chief Executive Officer · Q2 2026 earnings call, August 2026

“AI is now a major structural tailwind for us”

Serge Saxonov, Co-Founder and Chief Executive Officer · Q2 2026 earnings call, August 2026

“the overall gross margin profile of the Atera platform is superior to that of the Xenium platform”

Adam Taich, Chief Financial Officer · Q3 2026 earnings call, November 2026

Where a supplier can help

Manufacturing and installation capacity
Tied to the Atera ramp: production, installation and customer training are the stated constraint, so contract manufacturing, field service and training partners address the bottleneck directly.
AI compute and data partnerships
Tied to the AI and software priority: cloud, compute and data-platform providers can support Sentira and the AI model-training customers 10x serves.
Clinical lab build-out
Tied to the clinical-market priority: suppliers of CLIA lab equipment, quality systems and regulatory services can support the planned internal CLIA lab.
Supply chain resilience
Tied to the trade and supply chain challenge: alternative sources for reagents, enzymes and memory components reduce single-source and tariff exposure.
Biopharma market access
Tied to growing biopharma demand: partners with reach into biopharma research teams can help a company whose new Atera demand skews to biopharma as academic funding stays tight.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like 10x Genomics?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about 10x Genomics

What does 10x Genomics do?

10x Genomics makes instruments, consumables and software that let researchers analyse biology at single-cell and spatial resolution, through its Chromium, Visium, Xenium and Atera platforms.

What is 10x Genomics' revenue?

FY2025 revenue was $642.8 million, up 5%. FY2026 revenue is guided at $625 million to $635 million.

How many employees does 10x Genomics have?

It had 1,178 employees at December 31, 2025, 822 of them in the U.S.

Who leads 10x Genomics?

Co-founder Serge Saxonov is CEO and Adam Taich is CFO.

What is Atera?

Atera is 10x Genomics' new spatial platform for whole transcriptome profiling at single cell sensitivity; it began shipping in September 2026, with about 50 instruments expected by year-end.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)